<DOC>
	<DOCNO>NCT02081625</DOCNO>
	<brief_summary>This study design assess safety , tolerability , efficacy pharmacokinetics ( PK ) NS-065/NCNP-01 subject diagnose Duchenne muscular dystrophy ( DMD ) .</brief_summary>
	<brief_title>Exploratory Study NS-065/NCNP-01 DMD</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Subject Duchenne muscular dystrophy eligible enrolment study must meet following criterion : 1 . Has frame deletion ( ) could correct skip exon 53 confirm methodology time visit 1 . If confirm methodology evaluate relative copy number exon ( i.e . MLPA , CGH etc ) , must confirm technique time visit 4 . 2 . DNA sequence exon 53 confirms DNA polymorphism occur could compromise duplex formation NS065/NCNP01 premRNA . 3 . There confirmation detection dystrophin mRNA skip exon 53 dystrophin production vitro exposure NS065/NCNP01 subjectderived cell . 4 . Male &gt; = 5 year &lt; 18 year age time obtain informed consent and/or assent . 5 . Able give inform consent writing sign parent ( ) legal guardian able understand study procedure requirement . If applicable , able give inform assent write sign subject . 6 . Life expectancy least 1 year 7 . Unable ambulate . Ambulant subject enrol accord circumstance . 8 . Have intact muscle , adequate quality biopsy . ( No lack severe atrophy tibialis anterior muscle ) 9 . QTc &lt; 450 msec ( base 12lead ECGs ) , &lt; 480 msec subject Bundle Branch Block . 10 . If taking glucocorticosteroids , significant change total daily dosage dose regimen time visit 1 . Subject Duchenne muscular dystrophy meeting follow criterion must enrol study : 1 . Has participate pharmacological clinical trial might recover dystrophin protein readthrough exonskipping therapy , and/or upregulate dystrophinassociated protein utrophin . 2 . A forced vital capacity ( FVC ) &lt; 50 % predict . 3 . A left ventricular ejection fraction ( EF ) &lt; 40 % fractional shortening ( FS ) &lt; 25 % base echocardiogram ( ECHO ) . 4 . Surgery within last 3 month prior first anticipate administration study medication plan anytime duration study . 5 . Positive hepatitis B surface antigen ( HbsAg ) , hepatitis C antibody test ( HCV ) , human immunodeficiency virus ( HIV ) test screening . 6 . Current diagnosis immune deficiency autoimmune disease . 7 . Current diagnosis active uncontrolled infection , cardiomyopathy , liver renal disease . 8 . Use investigational agent and/or experimental agent within 3 month prior first anticipate administration study medication . 9 . History severe drug allergy . 10 . Unable give inform consent use adequate contraception first administration least 6 month last dose study medication , parent ( ) legal guardian . 11 . Subject consider investigator ( subinvestigator ) , reason , unsuitable candidate study .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Duchenne muscular dystrophy</keyword>
	<keyword>NS-065/NCNP-01</keyword>
	<keyword>exon 53 skip</keyword>
	<keyword>morpholino</keyword>
</DOC>